Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$1.50 USD
+0.28 (22.95%)
Updated Sep 26, 2025 04:00 PM ET
After-Market: $1.51 +0.01 (0.67%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PRLD 1.50 +0.28(22.95%)
Will PRLD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PRLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRLD
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know
After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD)
PRLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)
Other News for PRLD
Is PRLD showing upside potential? New Uptrend shows up after soaring 22.95%
PRLD rises 4.27% on September 25, leaving the technical picture intact
Is PRLD positioned for a breakout? Crossed Above 20 Day Moving Average shows up after rallying 13.59%
Stochastic Buy Signal appears for PRLD after 1.98% move
Crossed Above 50 Day Moving Average appears for PRLD after 2.56% move